Back to top
more

Intersect ENT, Inc. (XENT)

(Delayed Data from NSDQ)

$33.65 USD

33.65
406,200

+1.22 (3.76%)

Updated May 3, 2019 04:00 PM ET

After-Market: $33.66 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Intersect ENT Rides on Innovation Amid Pricing Concerns

by Zacks Equity Research

The SINUVA business line of Intersect ENT (XENT) makes a quick and remarkable progress with market access and field force balance.

Intersect ENT (XENT) Down 18.6% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Intersect ENT (XENT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Intersect (XENT) Q2 Loss Wider Than Estimates, Revenues Miss

by Zacks Equity Research

Intersect ENT's (XENT) lowered revenue guidance for 2019 raises concern.

Intersect ENT (XENT) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Intersect ENT (XENT) delivered earnings and revenue surprises of -5.88% and -1.36%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Intersect ENT (XENT) Q2 Earnings Expected to Decline

by Zacks Equity Research

Intersect ENT (XENT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Intersect ENT (XENT) Down 8.3% Since Last Earnings Report?

by Zacks Equity Research

Intersect ENT (XENT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Intersect (XENT) Q1 Loss Wider Than Estimates, Revenues Top

by Zacks Equity Research

Intersect (XENT) records revenue growth on increased adoption of the PROPEL family of products and SINUVA Sinus Implant.

Intersect ENT (XENT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Intersect ENT (XENT) delivered earnings and revenue surprises of -16.67% and 1.61%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Intersect ENT (XENT) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Intersect ENT (XENT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Intersect ENT Grows on Product Launch Amid Pricing Pressure

by Zacks Equity Research

Intersect ENT (XENT) recently finishes the ENCORE Study, which is a small 50-patient open label program, designed to evaluate the safety of the repeat use of SINUVA.

Analysts Estimate Intersect ENT (XENT) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Intersect ENT (XENT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Intersect ENT (XENT) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Intersect ENT (XENT) delivered earnings and revenue surprises of 3.85% and 2.26%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Intersect ENT (XENT) Q3 Earnings Preview: What to Watch Ahead of the Release

by Zacks Equity Research

Intersect ENT (XENT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Implied Volatility Surging for Intersect ENT (XENT) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Intersect ENT (XENT) stock based on the movements in the options market lately.

    Moving Average Crossover Alert: Intersect ENT (XENT)

    by Zacks Equity Research

    Intersect ENT, Inc. (XENT) could be a stock to avoid from a technical perspective

      Intersect ENT (XENT) Reports Q2 Loss, Misses Revenue Estimates

      by Zacks Equity Research

      Intersect ENT (XENT) delivered earnings and revenue surprises of 17.65% and -6.29%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

        Intersect ENT (XENT) SINUVA Implant Receives FDA Approval

        by Zacks Equity Research

        Intersect ENT's (XENT) consistent focus on the chronic sinusitis market is likely to lend the company a competitive edge in the niche space.

          The Zacks Analyst Blog Highlights: IDEXX Laboratories, Steris, K2M Group Holdings, Tandem Diabetes Care and Intersect ENT

          by Zacks Equity Research

          The Zacks Analyst Blog Highlights: IDEXX Laboratories, Steris, K2M Group Holdings, Tandem Diabetes Care and Intersect ENT

            5 MedTech Stocks for Stellar Returns in Q3

            by Zacks Equity Research

            Here we take a sneak peek into two burning issues that are likely to impact the quarterly numbers in the MedTech fraternity.

              The Saga to Revoke Obamacare Continues: 3 MedTech Picks

              by Zacks Equity Research

              In the wake of the turbulent political scenario and banking on favorable metrics, these three MedTech stocks stand out as the most suitable picks.

                Intersect ENT: FDA Submission of RESOLVE Implant, Stock Up

                by Zacks Equity Research

                Intersect ENT, Inc (XENT) recently announced the submission of a New Drug Application (NDA) approval with the U.S. FDA for reviewing its investigational RESOLVE steroid releasing implant.